A case of KSHV/HHV8-positive large B-cell lymphoma in a background of HIV-negative KSHV/HHV8-positive Multicentric Castleman disease

ElsevierVolume 31, Issue 12, December 2025, 102861Journal of Infection and ChemotherapyAuthor links open overlay panel, , , , , , , , , , Abstract

Lymphoproliferative disorders associated with human herpes virus 8 (HHV8) include Kaposi's sarcoma-associated herpesvirus (KSHV)/HHV8-positive multicentric Castleman disease (MCD), primary effusion lymphoma (PEL)/extracavitary PEL (EC-PEL), and KSHV/HHV8-positive diffuse large B-cell lymphoma (DLBCL). These lymphoproliferative disorders occur primarily in patients with HIV infection and immunodeficiency. HIV-negative KSHV/HHV8-positive MCD is extremely rare in Japan. We encountered a patient with KSHV/HHV8-positive large B-cell lymphoma with a history of HIV-negative, KSHV/HHV8-positive MCD. Although the KSHV/HHV8-positive MCD was in long-term remission with rituximab treatment, the patient developed refractory KSHV/HHV8-positive large B-cell lymphoma four years after the onset of MCD. The KSHV/HHV8-positive large B-cell lymphoma was refractory to chemotherapy, and the patient died. The course of this case suggests that HIV-negative KSHV/HHV-8-positive MCD may eventually lead to refractory KSHV/HHV8-positive large B-cell lymphoma, even after long-term remission with rituximab therapy.

Keywords

KSHV/HHV8-Positive large B-Cell lymphoma

KSHV/HHV8-Positive DLBCL

KSHV/HHV8-Positive multicentric castleman disease

KSHV/HHV8-Positive germinotropic LPD

© 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Comments (0)

No login
gif